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Abstract: Acne dysbiosis happens when there is a microbial imbalance of the over-growth of
Propionibacterium acnes (P. acnes) in the acne microbiome. In our previous study, we demonstrated that
Staphylococcus epidermidis (S. epidermidis, a probiotic skin bacterium) can exploit glycerol fermentation
to produce short-chain fatty acids (SCFAs) which have antimicrobial activities to suppress the growth
of P. acnes. Unlike glycerol, sucrose is chosen here as a selective fermentation initiator (SFI) that
can specifically intensify the fermentation activity of S. epidermidis, but not P. acnes. A co-culture of
P. acnes and fermenting S. epidermidis in the presence of sucrose significantly led to a reduction in the
growth of P. acnes. The reduction was abolished when P. acnes was co-cultured with non-fermenting
S. epidermidis. Results from nuclear magnetic resonance (NMR) analysis revealed four SCFAs (acetic
acid, butyric acid, lactic acid, and succinic acid) were detectable in the media of S. epidermidis sucrose
fermentation. To validate the interference of S. epidermidis sucrose fermentation with P. acnes, mouse
ears were injected with both P. acnes and S. epidermidis plus sucrose or phosphate buffered saline
(PBS). The level of macrophage-inflammatory protein-2 (MIP-2) and the number of P. acnes in ears
injected with two bacteria plus sucrose were considerably lower than those in ears injected with two
bacteria plus PBS. Our results demonstrate a precision microbiome approach by using sucrose as a
SFI for S. epidermidis, holding future potential as a novel modality to equilibrate dysbiotic acne.
Keywords: acne vulgaris; microbiome; P. acnes; S. epidermidis; skin; sucrose
1. Introduction
Microbial imbalance in the human skin microbiome [1,2] has been termed “skin dysbiosis” [3].
Here we refer to the precision microbiome as an approach for normalization of dysbiotic microbiome by
selectively targeting specific microbes. Propionibacterium acnes (P. acnes) and Staphylococcus epidermidis
(S. epidermidis) are two major bacterial inhabitants of lesions in acne vulgaris [2]. Although both P. acnes
and S. epidermidis are human skin commensals, the over-growth of P. acnes has been recognized for its
association with the progression of acne vulgaris [1,3]. The biological role of S. epidermidis within acne
lesions remains mysterious. During the development of acne vulgaris, S. epidermidis may irregularly
migrate from the outer surface of the skin into the hair follicle, where opportunistic strains of P. acnes
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exclusively habitate. A closed comedone (or a deep-seated abscess in an open comedone) creates an
anaerobic microenvironment which may facilitate bacterial fermentation in an acne lesion. Results
in our publication have demonstrated that S. epidermidis can ferment glycerol and create inhibition
zones to repel a colony of over-grown P. acnes [4]. Both topical and intralesional application of a
short-chain fatty acid (SCFA) produced by S. epidermidis glycerol fermentation into P. acnes-induced
lesions markedly suppressed the bacterial colonization and inflammation in mice [4]. Although
S. epidermidis is not well-defined as a probiotic bacterium, our previous results suggest that S. epidermidis
can exploit glycerol fermentation against P. acnes.
Both S. epidermidis and P. acnes can fermentatively metabolize glycerol to produce SCFAs [4,5].
Although the oppositional relationship between S. epidermidis and P. acnes in human skin has not yet
been clinically proven, we conjecture that, during the development of acne vulgaris, S. epidermidis and
P. acnes may use the glycerol as a shared carbon source and produce different SCFAs as antimicrobial
agents to compete against each other within an acne lesion. The acne vulgaris develops and persists
when P. acnes becomes dominant during the bacterial interference. Our approach to treating acne
vulgaris is to deter the over-growth of P. acnes by enhancing the fermentation activities of S. epidermidis
by using a specific sugar substrate as a selective fermentation initiator (SFI).
It has been reported that different bacterial species express distinct enzymes that ferment specific
sugar substrates [6,7]. Many bacteria use glucose, because they possess the enzymes required for
the degradation and oxidation of this sugar. Fewer bacteria are able to use complex carbohydrates
like disaccharides (lactose or sucrose) or polysaccharides (starch); these bacteria produce enzymes to
hydrolyse glycosidic bonds of disaccharides. The monosaccharides from degraded disaccharides
become new substrates for bacterial fermentation. S. epidermidis, but not Staphylococcus aureus
(S. aureus), can ferment mannose and galactose [6,7]. Our previous results showed that both
S. epidermidis and P. acnes, but not S. aureus (USA300), can fermentatively metabolize glycerol [8].
Although S. aureus bacteria utilize several carbohydrates as substrates for fermentation, they cannot
ferment ducitol (also called galactitol, a sugar alcohol) or saccharic acid [7]. Unlike glucose and
glycerol, which are endogenous metabolites in human skin, sucrose (C12H22O11)—a disaccharide
combination of glucose and fructose sugars—is found naturally in many fruits and vegetables. It has
been documented that sucrose is nonfermentable by P. acnes, and it has been used to reduce water
activity and hence bacterial colonization of wounds [9].
Antibiotics without bacterial specificity for acne treatment may destroy the fermenting bacteria
that help rein in the over-growth of P. acnes and maintain homeostasis of the acne microbiome.
At dermatology clinics, acne cyst injections by direct injection of corticosteroids into the nodule
can swiftly reduce redness and inflammation and help to immediately relieve the threat of scarring.
However, this injection can cause local side effects, including pigmentary changes and atrophy [10].
Benzoyl peroxide—a topical medication for acne vulgaris—can cause severe skin irritation. Isotretinoin
is a potent anti-acne agent derived from vitamin A [11]. However, it is strictly regulated because of
its known adverse effects on birth defects. However, it is strictly regulated due to the induction of
unwanted side effects. None of the above treatments selectively improve the fermentation activity
of commensal skin bacteria that may have a lower risk of developing side effects and resistant
P. acnes. Unlike vaccines, the action of probiotics does not directly require host immune stimulation,
and may have little or no disruption to other commensal bacteria. However, live S. epidermidis as
probiotics, when added exogenously into the open lesion/comedone of acne vulgaris, may be not
a viable option in patients with significant underlying health issues, such as surgical intervention
and immune suppression. In this study, we employ a precision microbiome approach by selective
augmentation of the fermentation activities of S. epidermidis against P. acnes. The development of
sucrose as a targeted intervention specifically for S. epidermidis fermentation may be relatively safe
when it is employed to rebalance dysbiotic acne.
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2. Results
2.1. Sucrose Selectively Triggered S. epidermidis, but Not P. acnes, to Undergo Fermentation
To examine the sucrose fermentation activities of S. epidermidis and P. acnes, bacteria were
incubated in rich medium under anaerobic conditions in the presence of 20 g/L sucrose. Rich media
plus either sucrose or bacteria were used as controls. To monitor the fermentation process, phenol red
(a fermentation indicator) was added into the culture to assess SCFA production as a result of sucrose
fermentation. Only media in the culture of S. epidermidis (ATCC 12228), but not P. acnes (ATCC 6919),
with sucrose turned yellow (more acidic) after six days of incubation (Figure 1), indicating that sucrose
can selectively trigger S. epidermidis to undergo fermentation.
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Figure 1. Sucrose as a selective carbon source for Staphylococcus epidermidis (S. epidermidis) 
fermentation. (A) S. epidermidis (SE) or (B) Propionibacterium acnes (P. acnes, PA) (105 CFU/mL) was 
incubated in rich media (M) with or without 20 g/L sucrose (S) for six days. Rich media plus sucrose 
without bacteria was included as a control. S. epidermidis, but not P. acnes, fermented sucrose. A color 
change to yellow in the media (marked in a black frame and blue arrow) indicates that sucrose 
fermentation of S. epidermidis has occurred. Representative data from three independent experiments 
are shown. 
2.2. The Sucrose Fermentation of S. epidermidis Is Essential for Inhibition of P. acnes Growth 
To examine whether the sucrose fermentation of S. epidermidis hindered the growth of P. acnes, 
S. epidermidis and P. acnes were co-cultured in the presence or absence of sucrose. To establish a  
P. acnes-selective plate, media from the co-culture of S. epidermidis and P. acnes were spotted on a rich 
medium plate supplemented 10 μg/mL of furazolidone (Furoxone). We found that furazolidone at  
a concentration of 10 μg/mL can completely kill S. epidermidis without affecting the growth of  
P. acnes (data not shown). Three days after the co-culture of S. epidermidis and P. acnes with/without 
sucrose, media were spotted on a P. acnes-selective plate. After co-culture of S. epidermidis/P. acnes in 
the absence of sucrose, P. acnes formed 1.4 ± 0.29 × 105 CFUs on a plate. However, when sucrose was 
present in the co-culture, an approximately one log10 reduction in the number of P. acnes colonies  
(1.2 ± 0.01 × 104 CFUs) was observed (Figure 2A). These findings suggest that S. epidermidis mediated 
sucrose fermentation to interfere with the growth of P. acnes. 
To validate the essential role of S. epidermidis fermentation in the interference with the growth 
of P. acnes, we screened the fermentation activities of different S. epidermidis strains isolated from 
human fingertips. In the presence of sucrose, the media in the culture of a strain with a 16S rRNA 
sequence showing 99% identity to that in S. epidermidis ATCC 12228 [12] remained orange-red after 
six days of incubation (Figure S1). We thus define this strain as a non-fermenting S. epidermidis. 
When a co-culture of non-fermenting S. epidermidis with P. acnes was conducted in the presence of 
sucrose, no reduction in the number of P. acnes colonies was found (Figure 2B), suggesting that 
fermentation is required for S. epidermidis to restrain the growth of P. acnes. 
i 1. Sucrose as electiv arbon source for Staphylococcus epidermidis (S. epidermidis) fermentation.
(A) S. epidermidis (SE) or (B) Propionibacterium ac es (P. acnes, PA) (105 CFU/mL) was incubated in
rich media (M) with or without 20 g/L s crose (S) for six days. Rich media plus sucrose with ut
bacteria was included as a control. S. epidermidis, but not P. acnes, ferme ted sucrose. A color change to
yellow in the media (marked in a black frame and blue arrow) indicates that sucrose fermentation of
S. epidermidis has occurred. Representative data from three independent experiments are shown.
2.2. The Sucrose Fermentation of S. epidermidis Is Essential for Inhibition of P. acnes Growth
To examine whether the sucrose fermentation of S. epidermidis hindered the growth of P. acnes,
S. epidermidis and P. acnes were c -cultured in the pres nce or absence of sucrose. To establish a
P acnes-selective plate, m dia f om the co-culture of S. epidermidis and P. acnes were spotted on a rich
medium pla e suppl mented 10 µg/mL of f azolidone (Furoxo e). We found that furazolidone
at a concentration of 10 µg/mL can completely kill S. epidermidis without affecting the growth of
P. ac es (data not shown). Three days after he co-culture of S. epidermidis and P. acnes with/wi out
sucrose, media were spotted on a P. acn s-sele tive plate. After co-culture of S. epid rmidis P. acnes
in the absence of sucrose, P. ac es formed 1.4 ± 0.29 × 105 CFUs on a plate. However, when sucrose
was pr sent in the co-culture, an approximately one log10 reduction in the number of P. acnes colonie
(1.2 ± 0.01 × 104 CFUs) was observed (Figure 2A). These findings sugg st that S. epidermidis mediat d
sucrose fermentation to interfere with the growth of P. acnes.
To validate the essential role of S. epide midis fermentation in the interference with the growth of
P. acnes, we screened the fermentation activities of differ t S. epidermidis strains isolated from human
fingertips. In the pr s nce of sucrose, he media in the cultu of a strain with a 16S rRNA s quence
showi g 99% identity to that in S. epidermidis ATCC 12228 [12] remain d orange-red after six days of
inc bation (Figure S1). We thus define his strain as a non-fermenting S. epid rmidis. Whe a co-culture
of non-ferme ting S. epidermidis with P. acnes was conducted in the prese c of sucrose, no reduction
in the number of P. acnes colonies was found (Figure 2B), suggesting that fermentation is required f r
S. epid rmidis to restrain the growth of P. acnes.
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Figure 2. The essential role of sucrose fermentation of S. epidermidis in the inhibition of the growth of 
P. acnes. (A) Fermenting S. epidermidis (ATCC 12228) or (B) non-fermenting S. epidermidis (106 CFU) 
were co-incubated with P. acnes (106 CFU) in 10 mL rich media with or without 20 g/L sucrose  
for three days. After incubation, culture media containing bacteria were diluted 1:10–1:105 with 
phosphate buffered saline (PBS) and then spotted the dilution (5 μL) onto P. acnes selective agar 
plates which contain rich media and 10 μg/mL of furazolidone. The number of P. acnes six days after 
incubation is expressed as log10 CFU/mL. Data are the mean ± standard deviation (SD) of three 
separate experiments. * p < 0.05 (two-tailed t-tests). n.s. = not significant. 
2.3. Identified SCFAs in Fermented Media of S. epidermidis 
To identify the SCFAs during fermentation, 13C12-sucrose (20 g/L) was added into the culture of 
S. epidermidis (ATCC 12228) under anaerobic conditions for six days. Supernatants of bacterial 
culture were mixed with 10% deuterium oxide (D2O) for one-dimensional (1-D) (data not shown) 
and two-dimensional (2-D) (Figure 3) 13C and 1H nuclear magnetic resonance (NMR) analysis. 
Besides un-metabolized sucrose, four SCFAs (acetic, butyric, lactic, and succinic acids) were 
detected in the fermented media of S. epidermidis, demonstrating the bacterial capability of 
fermentatively metabolizing sucrose into SCFAs. These results demonstrate that S. epidermidis 
fermentatively metabolized 13C12-sucrose into SCFAs. Results in our previous publication have 
demonstrated that SCFAs can suppress the growth of P. acnes ATCC 6919 [4]. To examine if SCFAs 
have the ability to kill P. acnes strains isolated from acne lesions, the minimum bactericidal 
concentration (MBC) value of acetic acid for a P. acnes strain isolated from acne lesion was 
determined (Figure S2). P. acnes was incubated with varying concentrations (0, 5, 7.5, 10, 25 and  
50 mM) of acetic acid overnight at 37 °C. After incubation, bacteria diluted with PBS were spotted 
on an agar plate for counting the colony forming units (CFU). Acetic acid reduced the P. acnes 
growth by more than one log10 at a concentration greater than 7.5 mM, and completely killed P. acnes 
at a concentration higher than 25 mM. These results suggest that SCFAs produced by sucrose 
fermentation of S. epidermidis may be able to impede the growth of P. acnes in acne vulgaris. 
Figure 2. The essential role of sucrose fermentation of S. epidermidis in the inhibition of the growth of
P. acnes. (A) Fermenting S. epidermidis (ATCC 12228) or (B) non-fermenting S. epidermidis (106 CFU) were
co-incubated with P. acnes (106 CFU) in 10 mL rich media with or without 20 g/L sucrose for three days.
After incubation, culture media containing bacteria were diluted 1:10–1:105 with phosphate buffered
saline (PBS) and then spotted the dilution (5 µL) onto P. acnes selective agar plates which contain rich
media and 10 µg/mL of furazolidone. The number of P. acnes six days after incubation is expressed as
log10 CFU/mL. Data are the mean ± standard deviation (SD) of three separate experiments. * p < 0.05
(two-tailed t-tests). n.s. = not significant.
2.3. Identified SCFAs in Fermented edia of S. epidermidis
To identify the SCFAs during fer entation, 13C12-sucrose (20 g/L) was added into the culture
of S. epidermidis (ATCC 12228) under anaerobic conditions for six days. Supernatants of bacterial
culture were ixed with 10% deuteriu oxide (D O) for one-di ensional (1-D) (data not shown)
and two-di ensional (2-D) (Figure 3) 13C and 1H nuclear agnetic resonance (N R) analysis.
Besides un-metabolized sucrose, four SCFAs (acetic, butyric, lactic, and succinic acids) were detected
in the fermented media of S. epidermidis, demonstrating the bacterial capability of fermentatively
metabolizing sucrose into SCFAs. These results demonstrate that S. epidermidis fermentatively
metabolized 13C12-sucrose into SCFAs. Results in our previous publication have demonstrated that
SCFAs can suppress the growth of P. acnes ATCC 6919 [4]. To examine if SCFAs have the ability to
kill P. acnes strains isolated from acne lesions, the minimum bactericidal concentration (MBC) value
of acetic acid for a P. acnes strain isolated from acne lesion was determined (Figure S2). P. acnes as
incubated with varying concentrations (0, 5, 7.5, 10, 25 and 50 mM) of acetic acid overnight at 37 ◦C.
After incubation, bacteria diluted with PBS were spotted on an agar plate for counting the colony
forming units (CFU). Acetic acid reduced the P. acnes growth by more than one log10 at a concentration
greater than 7.5 mM, and completely killed P. acnes at a concentration higher than 25 mM. These results
suggest that SCFAs produced by sucrose fermentation of S. epidermidis may be able to impede the
growth of P. acnes in acne vulgaris.
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Figure 3. Short-chain fatty acid (SCFA) identification by NMR analysis. The media of S. epidermidis 
13C12-sucrose fermentation were centrifuged and passed through a 0.2 μm filter. Supernatants were 
then mixed with 10% D2O and analyzed by NMR spectrometers. A 2-D 1H-13C HSQC NMR 
spectrum (600 MHz) was displayed. The un-metabolized 13C12-sucrose (solid arrows) appears 2.5–6.0 
and 50–100 ppm in the 1H- and 13C-NMR spectra, respectively. Besides sucrose, four SCFAs (acetic 
(Ac), butyric (BA), lactic (LA), and succinic acids (SA), open arrows) were detected in the ferments 
of S. epidermidis. 
2.4. S. epidermidis Sucrose Fermentation Abrogated P. acnes-Induced Inflammation and Bacteria 
Colonization In Vivo 
To test whether S. epidermidis can counteract P. acnes in the presence of sucrose, the ears of 
Institute for Cancer Research (ICR) mice were injected intradermally with P. acnes (107 CFU) and  
S. epidermidis (107 CFU) in the presence of sucrose (20 g/L) or PBS for three days. As shown in  
Figure 4, compared to those in the mice injected with two bacteria and PBS, both ear redness and 
thickness in the mice injected with two bacteria and sucrose was significantly lower (Figure 4A,B). 
To determine whether S. epidermidis sucrose fermentation can ameliorate the production of  
P. acnes-induced pro-inflammatory cytokines, mouse ears were excised and homogenized three days 
after injection. The level of macrophage-inflammatory protein-2 (MIP-2)—a murine counterpart of 
human interleukin (IL) 8—was measured by an enzyme-linked immunosorbent assay (ELISA). 
MIP-2 production in the ear injected with two bacteria and sucrose was approximately 75% (solid 
bar; 0.84 ± 0.17 × 104 pg/mL) less than that detected in the ear injected with two bacteria and PBS 
(open bar; 3.26 ± 0.51 × 104 pg/mL) (Figure 4C). 
To explore if S. epidermidis sucrose fermentation can hinder the growth of P. acnes, the ears of 
mice injected with two bacteria along with sucrose or phosphate buffered saline (PBS) were excised 
and homogenized. As shown in Figure 4D, the number of P. acnes recovered from mouse ears 
administered with two bacteria plus sucrose (solid bar; 6.0 ± 0.07 × 104 CFUs) was much lower than 
that recovered from ears administered with two bacteria plus PBS (open bar; 12.9 ± 1.1 ×105 CFUs), 
suggesting the suppression of P. acnes growth by S. epidermidis sucrose fermentation. 
Figure 3. Short-chain fatty acid (SCFA) identification by NMR analysis. The media of S. epidermidis
13C12-sucrose fermentation were centrifuged and passed through a 0.2 µm filter. Supernatants were
then mixed with 10% D2O and analyzed by NMR spectrometers. A 2-D 1H-13C HSQC NMR spectrum
(600 MHz) was displayed. The un-metabolized 13C12-sucrose (solid arrows) appears 2.5–6.0 and
50–100 ppm in the 1H- and 13C-NMR spectra, respectively. Besides sucrose, four SCFAs (acetic
(Ac), butyric (BA), lactic (LA), and succinic acids (SA), open arro s) ere detected in the fer ents
of S. epider idis.
2.4. S. epidermidis Sucrose Fermentation Abrogated P. acnes-Induced Inflammation and Bacteria Colonization
In Vivo
o test whether S. epidermidis can counteract P. acnes in the presence of sucrose, the ears of Institute
for Cancer Research (ICR) mice were injected intradermally with P. acnes (107 CFU) and S. epidermidis
(107 CFU) in the presence of sucrose (20 g/L) or PBS for three days. As shown in Figure 4, compared
to those in the mice injected with two bacteria and PBS, both ear redness and thickness in the mice
injected with two bacteria and sucrose was significantly lower (Figure 4A,B). To determine whether
S. epidermidis sucrose fermentation can ameliorate the production of P. acnes-induced pro-inflammatory
cytokines, mouse ears were excised and ho ogenized three days after injection. The level of
macrophage-inflammatory protein-2 (MIP-2)—a urine counterpart of human interleukin (IL) 8—was
measured by an enzyme-linked immunosorbent assay (ELISA). MIP-2 production in the ear injected
with two bacteria and sucrose was approximately 75% (solid bar; 0.84 ± 0.17 × 104 pg/mL) less
than that detected in the ear injected with two bacteria and PBS (open bar; 3.26 ± 0.51 × 104 pg/mL)
(Figure 4C).
To explore if S. epidermidis sucrose fermentation can hinder the growth of P. acnes, the ears of mice
injected with two bacteria along with sucrose or phosphate buffered saline (PBS) were excised and
homogenized. As shown in Figure 4D, the number of P. acnes recovered from mouse ears administered
with two bacteria plus sucrose (solid bar; 6.0 ± 0.07 × 104 CFUs) was much lower than that recovered
from ears administered with two bacteria plus PBS (open bar; 12.9 ± 1.1 ×105 CFUs), suggesting the
suppression of P. acnes growth by S. epidermidis sucrose fermentation.
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Figure 4. In Vivo reduction of P. acnes colonization and inflammation by S. epidermidis sucrose 
fermentation. The ears of Institute for Cancer Research (ICR) mice were injected intradermally with 
P. acnes (ATCC 6919) (107 CFU) and S. epidermidis (ATCC 12228) (107 CFU) with sucrose (20 g/L in  
10 μL PBS) or 10 μL PBS. (A) A photo of ear inflammation was taken three days after injection;  
(B) The ear thickness (mm); (C) The levels of macrophage-inflammatory protein-2 (MIP-2) cytokines 
in the ears injected with bacteria in the presence of sucrose or PBS was measured by an 
enzyme-linked immunosorbent assay (ELISA) kit; (D) The CFUs in the ears injected with bacteria in 
the presence of sucrose or PBS were enumerated by plating serial dilutions (1:10–1:105) of the 
homogenate on an agar plate. Three days after injection, p-values were evaluated using two-tailed 
t-tests. Data are the means of three separate experiments using four mice per group. *** p < 0.001;  
* p < 0.05. 
3. Discussion 
Sugars hold inherent antibacterial properties, some of which are due to high osmotic pressure 
and low water activity, which is inhibitory to the growth of bacteria [13]. It has been reported  
that the inhibitory effect of sucrose against S. aureus was primarily attributed to its water 
activity-lowering ability [14]. To examine the possible antibacterial activity of sucrose, we incubated 
P. acnes or S. epidermidis with 2% (20 g/L) sucrose overnight. As shown in Figure S3, incubation of 2% 
sucrose did not affect the growth of P. acnes or S. epidermidis. The result suggests that a decrease in 
the number of P. acnes in the co-culture of S. epidermidis and P. acnes with 2% sucrose (Figure 2A) 
primarily resulted from S. epidermidis sucrose fermentation, not antibacterial property of sucrose. As 
shown in Figure 3, four SCFAs were produced in the fermented media of S. epidermidis. Results in 
our previous papers demonstrated that pH buffering does not influence the antimicrobial activities 
of SCFAs [15]. Furthermore, SCFAs can passively diffuse through the cell wall of bacteria and kill 
bacteria by lowering the intracellular pH [8]. Findings above suggested that the suppression of  
P. acnes growth in a co-culture assay (Figure 2) and by acetic acid (Figure S2) was not simply due to 
the acidities of SCFAs in media. 
By employing an approach of precision programming of the acne microbiome, we use sucrose 
as a SFI for S. epidermidis in this study. Phage therapy is a precision microbiome approach wherein 
scientists use bacteriophages specifically targeting pathogens without damaging the commensal 
bacteria of the host [16]. Although bacteriophages can be highly bacteria-specific, many 
disadvantages of phage therapy have been documented [17]. For example, for the selection of 
Figure 4. In Vivo reduction of P. acnes colonization and infla ation by S. epider idis sucrose
fer entation. The ears of Institute for ancer esearch (I ) ice ere injected intrader ally ith
. acnes ( 6919) (10 F ) and S. epidermidis (ATCC 12228) (107 CFU) with sucrose (20 g/L
in 10 µL PBS) or 10 µL PBS. (A) A photo of ear infla mation was taken three ays after i jectio ;
( ) e ear t ic ess ( ); (C) The levels of macrophage-inflam atory protein-2 (MIP-2) cytokines in
the ears injected with bacteria in the presence of sucrose or PBS was measured by an enzyme-linked
immunosorbent assay (ELISA) kit; (D) The CFUs in the ears injected with bact ria in the presence of
sucros or PBS were enume ated by plating serial dilutions (1:10–1:105) of the homogenate on an agar
plate. Three days after injection, p-values were evaluated using two-tail d t-tests. Data are he means
of three separate experiments using four mice per group. *** p < 0.001; * p < 0.05.
3. Discussion
Sugars hold inherent antibacterial properties, some of which are due to high osmotic pressure
and low water activity, which is inhibitory to the growth of bacteria [13]. It has been reported that the
inhibitory effect of sucrose against S. aureus was primarily attributed to its water activity-lowering
ability [14]. To examine the possible antibacterial activity of sucrose, we incubated P. acnes or
S. epidermidis with 2% (20 g/L) sucrose overnight. As shown in Figure S3, incubation of 2% sucrose
did not affect the growth of P. acnes or S. epidermidis. The result suggests that a decrease in the
number of P. acnes in the co-culture of S. epidermidis and P. acnes with 2% sucrose (Figure 2A) primarily
resulted from S. epidermidis sucrose fermentation, not antibacterial property of sucrose. As shown
in Figure 3, four SCFAs were produced in the fermented media of S. epidermidis. Results in our
previous papers demonstrated that pH buffering does not influence the antimicrobial activities of
SCFAs [15]. Furthermore, SCFAs can passively diffuse through the cell wall of bacteria and kill bacteria
by lowering the intracellular pH [8]. Findings above suggested that the suppression of P. acnes growth
in a co-culture assay (Figure 2) and by acetic acid (Figure S2) was not simply due to the acidities of
SCFAs in media.
By employing an approach of precision programming of the acne microbiome, we use sucrose as a
SFI for S. epidermidis in this study. Phage therapy is a precision microbiome approach wherein scientists
use bacteriophages specifically targeting pathogens without damaging the commensal bacteria of the
host [16]. Although bacteriophages can be highly bacteria-specific, many disadvantages of phage
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therapy have been documented [17]. For example, for the selection of bacteriophages as potential
safe antimicrobials, detailed comprehensive characteristics of genome and phenotypic properties
may be required, since bacteriophages contain negative features such as lysogeny-associated genes,
toxin or enzyme encoding genes [18]. Furthermore, scientists do not yet fully appreciate the safety
issue of phage therapy, because many identified genes of bacteriophages express hypothetical and
putative proteins with predicted or unknown functions. An additional drawback of phage therapy
is that bacteriophages can transfer their genes from one microbe to another. Sucrose—a substance
of extremely low acute toxicity—is Generally Recognized As Safe (GRAS) by the US Food and Drug
Administration (FDA). With hygroscopic properties, sucrose is commonly used in hair and skin care
products to retain moisture. Although sucrose is used here as a SFI for S. epidermidis, future studies
will include determining whether sucrose influences the growth and fermentation activity of other
commensal bacteria—especially S. aureus—in skin.
Genetic loci responsible for sucrose fermentation of S. epidermidis have not been described. Several
enzymes (e.g., permease) regulate the movement of carbohydrates across the bacterial cell wall [19].
We believe that sucrose fermentation, an anaerobic process, also requires many intracellular enzymes
that degrade sucrose to SCFAs. Once the key enzyme in charge of sucrose fermentation is determined,
a mutant strain of S. epidermidis with a deficiency in this enzyme can be created to validate the
essential role of fermentation in the suppression of P. acnes growth. Low levels of SCFAs in the human
bloodstream were detected, ranging from 3 to 7 µM [20]. However, the intestinal microbes in the
human colon can locally produce high levels (20–140 mM) of SCFAs [20] that can sufficiently kill
pathogens. Although we have not determined how many SCFAs can be locally produced when
sucrose is applied to the microenvironment of an acne lesion, it has been documented that SCFAs with
short half-lives have apparent difficulty achieving pharmacologic concentrations In Vivo [21]. Several
pro-drugs of butyric acid (e.g., pivaloylomethyl butyrate; AN-9) [21] have been developed to achieve
effective concentrations of butyric acid. SCFAs act on host cells through at least two mechanisms:
inhibition of histone deacetylase (HDAC) and activation of free fatty acid receptors (Ffar1; also known
as G-protein coupled receptor 41 (GPR41) and Ffar2; GPR43) [22]. The expression of Ffar1 [23] and
Ffar2 [24] in acne lesions is not yet quantified. Several HDAC inhibitors with anti-inflammatory
activities are in preclinical and clinical development, including AN-9. Butyric acid is a small molecular
weight carboxylate that is a class I HDAC inhibitor [25]. Propionic and butyric acids have been
verified as ligands of Ffar1 [26]. Previous studies showed that GW9508 (GlaxoSmithKline)—an
arylalkyl derivative of propionic acid—activated the Ffar1 receptor, suppressed chemokine induction
in keratinocytes, and attenuated cutaneous immune inflammation [27]. P. acnes can activate toll-like
receptor 2 (TLR-2) [28] to stimulate the secretion of IL-6 and IL-8 by follicular keratinocytes, and
IL-1β, tumor necrosis factor alpha (TNFα), IL-8, and IL-12 by monocytic cells [29]. As shown in
Figure 4C, we demonstrated a reduction of MIP-2 cytokine when mouse ear was injected with P. acnes
and S. epidermidis in the presence of sucrose. It is possible that SCFAs produced by S. epidermidis
attenuate P. acnes-induced inflammation via the inhibition of HDACs or the activation of Ffar1 or
Ffar2. Our previous studies have demonstrated that a co-drug—butyric acid 2-(2-butyryloxyethoxy)
ethyl ester—can release two active butyric acids in mice (data not shown). A co-drug—propionic acid
2-(2-propionyloxy-ethoxy)-ethyl ester—exerts antimicrobial activity [15]. Application of these co-drugs
onto acne lesions may conquer the drawbacks of SCFAs with short half-lives for acne treatments.
Our results in Figure 4 show that intradermal injection of P. acnes into mouse ears provoked a
significant granulomatous response, which was characterized as a lesion of epithelioid macrophages,
frequently bounded by a lymphocyte cuff [30]. In the event of severe acne vulgaris, P. acnes could
move into the dermal layer once the follicular wall was ruptured [31]. Injection of P. acnes into mouse
ears may represent an animal model for the granulomatous type of inflammatory acne vulgaris that
follows follicular rupture. P. acnes has been subdivided into at least two types (I and II), and two
subtypes, IA and IB [32]. A recent study demonstrated that an acne lesion in humans consists of
mixed P. acnes phenotypes [33]. Although we do not know which subtypes of P. acnes we isolated from
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acne lesions (Figure S2), the development of SCFA co-drugs that can specifically suppress the growth
of acne-associated P. acnes subtypes may be necessary to avoid the disruption of the homeostasis of
commensal P. acnes subtypes. We also do not know whether all strains of S. epidermidis in acne lesions
have equal abilities to ferment sucrose. It has been reported that IL-8 was expressed at a higher level
in acne lesions than that in healthy skin [34]. As shown in Figure S4A, the level of IL-8 cytokine was
significantly reduced when an acne lesion was incubated with (20 g/L) sucrose for 24 h. P. acnes
bacteria in acne lesions were detected by immunohistochemical staining with a monoclonal antibody
against a surface sialidase protein of P. acnes. Incubation of sucrose significantly lowered the numbers
of P. acnes in acne lesions (Figure S4B–F). A clinical study with additional acne lesions to determine
the production of SCFAs by sucrose fermentation and the efficacy of sucrose as a SFI for S. epidermidis
against P. acnes in acne lesions may be required in the future.
Clindamycin and erythromycin are commonly-prescribed topical antibiotics for acne vulgaris [35].
Antibiotic single-agent therapy can result in rapid development of clinically significant antibiotic
resistance [36]. Several sugars have been added into antibiotic formula as ingredients. For example,
sucrose is often added into amoxicillin for formulation [37]. An adjuvant is a pharmacological or
immunological agent that modifies the effect of a drug or vaccine. Formulation of an antibiotic with
sucrose which functions as an adjuvant may potentiate the effect of the antibiotic on killing of P. acnes.
The development of sucrose as post-antibiotic adjuvant therapy [38] may lower the required dose of
antibiotic for the treatment of acne vulgaris, decreasing the risk of generating resistant P. acnes and
non-specific killing effect of antibiotics on skin commensal bacteria.
4. Experimental Section
4.1. Ethics Statement
Experiments using mice were performed at National Central University (NCU). The NCU ethics
committee specifically approved this study (ID: 104-2320-B-008-003) on August 01, 2015 under an
approved Institutional Animal Care and Use Committee (IACUC) protocol.
4.2. Bacterial Culture
S. epidermidis bacteria, including ATCC 12228 and non-fermenting S. epidermidis isolated from
human skin, were cultured on 3% tryptic soy broth (TSB) (Sigma, St. Louis, MO, USA) agar plates
overnight at 37 ◦C. P. acnes bacteria (ATCC 6919) were cultured on Brucella broth agar plates,
supplemented with 5% (v/v) vitamin K (Remel, Lenexa, KS, USA) and hemin (Remel) under anaerobic
conditions using Gas-Pak (BD Biosciences, San Jose, CA, USA) at 37 ◦C with shaking at 200 rpm.
A single colony was inoculated in 3% TSB and Reinforced Clostridium Medium (Oxford, UK) and
cultured at 37 ◦C until the logarithmic growth phase. Bacterial pellets were harvested by centrifugation
at 5000× g for 10 min, washed with PBS, and suspended in PBS.
4.3. Fermentation of Bacteria
S. epidermidis and P. acnes bacteria (105 CFU/mL) were incubated in 10 mL rich media (10 g/L
yeast extract (Biokar Diagnostics, Beauvais, France), 3 g/L TSB, 2.5 g/L K2HPO4, and 1.5 g/L KH2PO4)
in the absence and presence of 20 g/L sucrose under anaerobic conditions at 37 ◦C with shaking
at 200 rpm. The rich media plus 20 g/L sucrose without bacteria were included as a control.
The 0.002% (w/v) phenol red (Sigma, St. Louis, MO, USA) in rich media with 20 g/L sucrose acted
as a fermentation indicator. A color change from red-orange to yellow indicated the occurrence of
bacterial fermentation.
4.4. Co-Culture Assays
S. epidermidis (106 CFU) and P. acnes (106 CFU) bacteria were co-incubated in 10 mL rich media
with or without 20 g/L sucrose under anaerobic conditions for three days at 37 ◦C with shaking
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at 200 rpm. After incubation, bacteria were diluted 1:10–1:105 with PBS and then spotted the dilution
(5 µL) onto P. acnes selective agar plates containing rich media and 10 µg/mL of furazolidone
(Sigma) [39]. The CFUs of P. acnes were counted after incubation at 37 ◦C for six days.
4.5. NMR Analysis
S. epidermidis (ATCC 12228) (105 CFU/mL) bacteria were incubated in rich media in the presence
of 13C12-sucrose (20 g/L) (Omicron Biochemicals, Inc., South Bend, USA) for six days. The 1-D
NMR spectra of SCFAs were obtained via a 400 MHz JEOL-ECS NMR spectrometer. The 2-D 1H-13C
heteronuclear single quantum correlation (HSQC) spectra of SCFAs were acquired on a Bruker Avance
600 MHz NMR spectrometer with a triple resonance inverse (TCI) cryo-probe. The 2048× 256 complex
data points were recorded with 32 scans and a repetition time of 1 s, as previously described in
detail [4]. Newly appearing peaks are the intermediate or final products produced by 13C12-sucrose
fermentation of S. epidermidis.
4.6. The Sucrose Fermentation of S. epidermidis against P. acnes In Vivo
The ICR mice (2–3-month-old females; Harlan Labs, Placentia, CA, USA) were anesthetized
by isoflurane (Sigma). Five mice per group were used in each experiment. The ears of ICR mice
were injected intradermally with P. acnes (ATCC 6919) (107 CFU) and S. epidermidis (ATCC 12228)
(107 CFU) with sucrose (20 g/L in 10 µL PBS) or 10 µL PBS using an insulin syringe with 29 G × 1/2
inches (BD Biosciences, San Jose, CA, USA). After three days, ear thickness was measured with an
electronic digital caliper (Mitutoyo, Kanagawa, Japan). Ears were excised, weighed, and homogenized
for cytokine detection and bacterial counts. The total protein concentration was measured by a Pierce
BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA).
4.7. Bacterial Loads in Mouse Ears
After excising mouse ears, tissue homogenates were made by a tissue grinder in 200 µL of sterile
PBS. CFUs of P. acnes in ear homogenates were enumerated by plating serial dilutions (1:10–1:105) of
homogenates on P. acnes selective agar plates containing rich media and 10 µg/mL of furazolidone
(Sigma). After that, plates were incubated for three days at 37 ◦C under anaerobic conditions using
Gas-Pak. A biosafety level 2 (BSL-2) facility was used for conduction of mouse experiments in
accordance with institutional guidelines for animal experiments.
4.8. ELISA
The MIP-2 in the supernatants of ear homogenates was quantified by an ELISA kit, as directed by
the manufacturer (R&D System. Inc., Minneapolis, MN, USA).
4.9. Statistics
Experiments were repeated at least three times with similar results. Statistical significance was
determined using Student’s unpaired two-tailed t-test, as indicated in the legend (* p < 0.05, ** p < 0.01,
*** p < 0.001).
5. Conclusions
Overall, in this study, sucrose was able to specifically intensify the probiotic ability of S. epidermidis,
producing SCFAs which can potentially suppress the inflammation and growth of P. acnes. The novel
acne treatment using sucrose as a SFI for probiotic S. epidermidis may benefit the entire community of
patients with acne vulgaris, consisting of over 50,000 patients in the US [40].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1870/s1.
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Abbreviations
Ac acetic acid
ATCC American Type Culture Collection
BA butyric acid
CFU colony-forming unit
BSL-2 biosafety level 2
1-D one-dimensional
2-D two-dimensional
D2O deuterium oxide
ELISA enzyme-linked immunosorbent assay
FDA Food and Drug Administration
Ffar1 free fatty acid receptor 1
Ffar2 free fatty acid receptor 2
GPR41 G-protein coupled receptor 41
GRAS Generally Recognized As Safe
HDAC histone deacetylase
HSQC heteronuclear single quantum coherence
IACUC Institutional Animal Care and Use Committee
IL interleukin
MIP-2 macrophage-inflammatory protein-2
NCU National Central University
NIH National Institutes of Health
NF-S. epidermidis non-fermentation S. epidermidis
NMR nuclear magnetic resonance
NS non-significant
P. acnes Propionibacterium acnes
PBS phosphate buffered saline
SCFA short-chain fatty acids
SD standard deviation
S. epidermidis Staphylococcus epidermidis
SFI selective fermentation initiator
16S rRNA 16S ribosomal RNA
TLR-2 toll-like receptor 2
TNFα tumor necrosis factor α
References
1. Grice, E.A.; Segre, J.A. The skin microbiome. Nat. Rev. Microbiol. 2011, 9, 244–253. [CrossRef] [PubMed]
2. Kong, H.H.; Segre, J.A. Skin microbiome: Looking back to move forward. J. Investig. Dermatol. 2012, 132,
933–939. [CrossRef] [PubMed]
3. Scanlan, P.D.; Buckling, A.; Kong, W.; Wild, Y.; Lynch, S.V.; Harrison, F. Gut dysbiosis in cystic fibrosis.
J. Cyst. Fibros. 2012, 11, 454–455. [CrossRef] [PubMed]
4. Wang, Y.; Kuo, S.; Shu, M.; Yu, J.; Huang, S.; Dai, A.; Two, A.; Gallo, R.L.; Huang, C.M. Staphylococcus
epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of propionibacterium
acnes: Implications of probiotics in acne vulgaris. Appl. Microbiol. Biotechnol. 2014, 98, 411–424. [CrossRef]
[PubMed]
5. Moss, C.W.; Dowell, V.R., Jr.; Lewis, V.J.; Schekter, M.A. Cultural characteristics and fatty acid composition
of corynebacterium acnes. J. Bacteriol. 1967, 94, 1300–1305. [PubMed]
6. Robbins, G.B.; Lewis, K.H. Fermentation of sugar acids by bacteria. J. Bacteriol. 1940, 39, 399–404. [PubMed]
7. Safonova, T.B.; Shcherbakova, N.A.; Afanas’eva, T.I.; Sobolev, V.R. Importance of carbohydrate tests for
interspecies differentiation of staphylococci. Zh. Mikrobiol. Epidemiol. Immunobiol. 1978, 9, 98–101.
Int. J. Mol. Sci. 2016, 17, 1870 11 of 12
8. Shu, M.; Wang, Y.; Yu, J.; Kuo, S.; Coda, A.; Jiang, Y.; Gallo, R.L.; Huang, C.M. Fermentation of
propionibacterium acnes, a commensal bacterium in the human skin microbiome, as skin probiotics against
methicillin-resistant staphylococcus aureus. PLoS ONE 2013, 8, e55380. [CrossRef] [PubMed]
9. Eady, E.A.; Layton, A.M.; Cove, J.H. A honey trap for the treatment of acne: Manipulating the follicular
microenvironment to control propionibacterium acnes. BioMed Res. Int. 2013, 2013. [CrossRef] [PubMed]
10. Levine, R.M.; Rasmussen, J.E. Intralesional corticosteroids in the treatment of nodulocystic acne.
Arch. Dermatol. 1983, 119, 480–481. [CrossRef] [PubMed]
11. Layton, A.M.; Dreno, B.; Gollnick, H.P.; Zouboulis, C.C. A review of the european directive for prescribing
systemic isotretinoin for acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 773–776. [CrossRef]
[PubMed]
12. Lindh, J.M.; Terenius, O.; Faye, I. 16s rRNA gene-based identification of midgut bacteria from field-caught
anopheles gambiae sensu lato and A. funestus mosquitoes reveals new species related to known insect
symbionts. Appl. Environ. Microbiol. 2005, 71, 7217–7223. [CrossRef] [PubMed]
13. Al-Naama, R.T. Evaluation of inhibitory effect of honey on some bacterial isolates. Iraqi J. Med. Sci. 2009,
7, 67–72.
14. Ballesteros, S.A.; Chirife, J.; Bozzini, J.P. Specific solute effects on staphylococcus aureus cells subjected to
reduced water activity. Int. J. Food Microbiol. 1993, 20, 51–66. [CrossRef]
15. Wang, Y.; Dai, A.; Huang, S.; Kuo, S.; Shu, M.; Tapia, C.P.; Yu, J.; Two, A.; Zhang, H.; Gallo, R.L.; et al.
Propionic acid and its esterified derivative suppress the growth of methicillin-resistant Staphylococcus aureus
USA300. Benef. Microbes 2014, 5, 161–168. [CrossRef] [PubMed]
16. Pincus, N.B.; Reckhow, J.D.; Saleem, D.; Jammeh, M.L.; Datta, S.K.; Myles, I.A. Strain specific phage treatment
for staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS ONE 2015, 10,
e0124280. [CrossRef] [PubMed]
17. Haq, I.U.; Chaudhry, W.N.; Akhtar, M.N.; Andleeb, S.; Qadri, I. Bacteriophages and their implications on
future biotechnology: A review. Virol. J. 2012, 9. [CrossRef] [PubMed]
18. Drulis-Kawa, Z.; Majkowska-Skrobek, G.; Maciejewska, B.; Delattre, A.S.; Lavigne, R. Learning
from bacteriophages—Advantages and limitations of phage and phage-encoded protein applications.
Curr. Protein Pept. Sci. 2012, 13, 699–722. [CrossRef] [PubMed]
19. Jahreis, K.; Pimentel-Schmitt, E.F.; Brückner, R.; Titgemeyer, F. Ins and outs of glucose transport systems in
eubacteria. FEMS Microbiol. Rev. 2008, 32, 891–907. [CrossRef] [PubMed]
20. Garland, S.H. Short chain fatty acids may elicit an innate immune response from preadipocytes: A potential
link between bacterial infection and inflammatory diseases. Med. Hypotheses 2011, 76, 881–883. [CrossRef]
[PubMed]
21. Hobdy, E.; Murren, J. AN-9 (Titan). Curr. Opin. Investig. Drugs 2004, 5, 628–634. [PubMed]
22. Vinolo, M.A.; Rodrigues, H.G.; Nachbar, R.T.; Curi, R. Regulation of inflammation by short chain fatty acids.
Nutrients 2011, 3, 858–876. [CrossRef] [PubMed]
23. Ulven, T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic
targets. Front. Endocrinol. 2012, 3. [CrossRef] [PubMed]
24. Gottlicher, M. Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases.
Ann. Hematol. 2004, 83, S91–S92. [PubMed]
25. Silva, F.; Serpa, J.; Domingues, G.; Silva, G.; Almeida, A.; Félix, A. Cell death induced by HDACS inhibitors
in ovarian cancer cell lines (serous and clear cells carcinomas)—Role of NOTCH, TP53 and FN1. BMC Proc.
2010, 4. [CrossRef]
26. Park, J.S.; Lee, E.J.; Lee, J.C.; Kim, W.K.; Kim, H.S. Anti-inflammatory effects of short chain fatty acids in
IFN-γ-stimulated RAW 264.7 murine macrophage cells: Involvement of Nf-κB and ERK signaling pathways.
Int. Immunopharmacol. 2007, 7, 70–77. [CrossRef] [PubMed]
27. Hara, T.; Hirasawa, A.; Ichimura, A.; Kimura, I.; Tsujimoto, G. Free fatty acid receptors FFAR1 and GPR120
as novel therapeutic targets for metabolic disorders. J. Pharm. Sci. 2011, 100, 3594–3601. [CrossRef] [PubMed]
28. Kim, J. Review of the innate immune response in acne vulgaris: Activation of toll-like receptor 2 in acne
triggers inflammatory cytokine responses. Dermatology 2005, 211, 193–198. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1870 12 of 12
29. Mastrofrancesco, A.; Kokot, A.; Eberle, A.; Gibbons, N.C.; Schallreuter, K.U.; Strozyk, E.; Picardo, M.;
Zouboulis, C.C.; Luger, T.A.; Bohm, M. KdPT, a tripeptide derivative of α-melanocyte-stimulating hormone,
suppresses IL-1β-mediated cytokine expression and signaling in human sebocytes. J. Immunol. 2010, 185,
1903–1911. [CrossRef] [PubMed]
30. Liu, P.F.; Nakatsuji, T.; Zhu, W.; Gallo, R.L.; Huang, C.M. Passive immunoprotection targeting a secreted
CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine 2011, 29,
3230–3238. [CrossRef] [PubMed]
31. Kligman, A.M. An overview of acne. J. Investig. Dermatol. 1974, 62, 268–287. [CrossRef] [PubMed]
32. Valanne, S.; McDowell, A.; Ramage, G.; Tunney, M.M.; Einarsson, G.G.; O’Hagan, S.; Wisdom, G.B.; Fairley, D.;
Bhatia, A.; Maisonneuve, J.F.; et al. CAMP factor homologues in Propionibacterium acnes: A new protein
family differentially expressed by types I and II. Microbiology 2005, 151, 1369–1379. [CrossRef] [PubMed]
33. Jahns, A.C.; Lundskog, B.; Ganceviciene, R.; Palmer, R.H.; Golovleva, I.; Zouboulis, C.C.; McDowell, A.;
Patrick, S.; Alexeyev, O.A. An increased incidence of propionibacterium acnes biofilms in acne vulgaris:
A case-control study. Br. J. Dermatol. 2012, 167, 50–58. [CrossRef] [PubMed]
34. Kelhälä, H.L.; Palatsi, R.; Fyhrquist, N.; Lehtimäki, S.; Väyrynen, J.P.; Kallioinen, M.; Kubin, M.E.; Greco, D.;
Tasanen, K.; Alenius, H.; et al. IL-17/Th17 pathway is activated in acne lesions. PLoS ONE 2014, 9, e105238.
[CrossRef] [PubMed]
35. Del Rosso, J.Q.; Schmidt, N.F. A review of the anti-inflammatory properties of clindamycin in the treatment
of acne vulgaris. Cutis 2010, 85, 15–24. [PubMed]
36. Zavascki, A.P.; Bulitta, J.B.; Landersdorfer, C.B. Combination therapy for carbapenem-resistant
Gram-negative bacteria. Expert Rev. Anti Infect. Ther. 2013, 11, 1333–1353. [CrossRef] [PubMed]
37. Soares, D.N.; Antonio, A.G.; Iorio, N.L.; Pierro, V.S.; dos Santos, K.R.; Maia, L.C. Does the presence of
sucrose in pediatric antibiotics influence the enamel mineral loss and the Streptococcus mutans counts in
dental biofilm? Braz. Dent. J. 2015, 26, 249–257. [CrossRef] [PubMed]
38. Hurley, M.N.; Forrester, D.L.; Smyth, A.R. Antibiotic adjuvant therapy for pulmonary infection in cystic
fibrosis. Cochrane Database Syst. Rev. 2013. [CrossRef]
39. Marino, C.; Stoughton, R.B. Clinical use of a selective culture medium for wild and antibiotic-resistant
propionibacterium acnes. J. Am. Acad. Dermatol. 1982, 6, 902–908. [CrossRef]
40. Fried, R.G.; Wechsler, A. Psychological problems in the acne patient. Dermatol. Ther. 2006, 19, 237–240.
[CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
